Development of new inhibitors as potential anti-tumor therapies, as well as for other conditions resulting from overexpression or activation of the Rho-ROCK-LIMK2 pathway, is still a highly desirable objective [7, 35, 38, 40]. This evidence concerns the gene LIMK2 and neoplasm.